platoseedplatoseed
Developing long-lasting drug formulations 50% faster
It takes 5 years for pharma to develop long lasting drug injections for chronic diseases like cancer and diabetes. Persist uses AI-driven automation to reduce formulation development time down to 2 years, a ~50% reduction.
Persist AI combines AI and robotics to accelerate pharmaceutical formulation development, focusing on long-acting injectables and related dosage forms. Their platform spans AI design, robotic execution, and end-to-end formulation optimization from molecule to in vivo-ready product.
Persist AI offers a cloud-based AI Suite that designs candidate formulations and a Cloud Lab where robotic systems execute experiments and feed results back to a centralized dashboard. The Release Platform combines AI-driven design with automated formulation development, enabling end-to-end workflow from molecule input to optimized formulation through iterative testing and data feedback.
Who it’s for: Biotech and pharmaceutical companies seeking rapid formulation development and optimization for long-acting injectables, amorphous solid dispersions, parenterals, creams, and in-situ depots.
funding (Series A) and partnerships mentioned
When mom got brain cancer, I used to take her for her "infusions". For 4 hours, we would sit there while drug was being infused into her veins and she had horrible nausea and hair loss. I built Persist to eradicate this horrible experience for future patients. We package drugs so that patients take 1 injection per month or year, without an infusion. This lowers the overall dose the patient receives (reducing side-effects), improves compliance, and quality of life.
Career program manager, first time founder. Focus has been in electronics, automation, and manufacturing. Super excited to be part of the YC batch!
Drug formulations made by robotics and designed by AI
Persist uses robotics and AI to encapsulate drugs in injectable microspheres for one-year release, aiming to shorten drug formulation from five years to about two years and enable faster, more scalable production for chronic-disease injections.
From the original launch (Feb 2023) — may be outdated.
Generative AI for protein design
Creating new protein-based drugs at scale
